Tempus AI Launches HRD-RNA Algorithm After Validation Study, Shares Gain 3.4%
Tempus AI unveiled its HRD-RNA algorithm to detect homologous recombination deficiency via transcriptome analysis, validated in metastatic pancreatic cancer patients showing significant mortality risk reduction with platinum-based therapies. Shares rose 3.41% and analysts maintain a Buy consensus with a $76.60 average price target and $364.25M revenue estimate.
1. Algorithm Launch and Technology
Tempus AI introduced the HRD-RNA algorithm, leveraging transcriptome analysis to assess homologous recombination deficiency in tumors. The tool examines gene expression dynamics rather than relying solely on genomic alterations, providing a functional view of HRD status and is slated for clinical availability later this year.
2. Validation Study Results
In a real-world study of metastatic pancreatic cancer, patients identified as HRD-RNA positive and treated with first-line platinum-based chemotherapy experienced a statistically significant reduction in mortality risk compared with those on non-platinum regimens. This outcome underscores the algorithm’s potential to guide more effective treatment selection.
3. Market Reaction and Technical Indicators
Following the announcement, shares of Tempus AI climbed 3.41% in premarket trading. Despite this gain, the stock remains 8.3% below its 20-day moving average and 25.8% below its 100-day moving average, reflecting ongoing short-term bearish momentum.
4. Analyst Consensus and Financial Outlook
Analysts hold a Buy consensus with an average price target of $76.60. The company is projected to report $364.25 million in Q4 revenue (up from $200.68 million year-over-year) and an EPS loss of $0.13, ahead of its February 24, 2026 earnings release.